Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the "**Company**") on a voluntary basis.

The Company is pleased to announce its sublicensed-in botulinum toxin type A for injection (DaxibotulinumtoxinA-lanm, with the trademark of 达希斐® in Chinese Mainland and the English trademark of DAXXIFY®, project code RT002, the "**DAXXIFY**"), which is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscles activity in adult patients, has passed the quality testing from National Institutes for Food and Drug Control of the People's Republic of China ("**China**").

As at the date of this announcement, there was no DaxibotulinumtoxinA-lanm product launched for sale in Chinese Mainland. The successful completion of this testing confirms that DAXXIFY has met the stringent quality, safety and efficacy standards of China's national drug regulatory system. Currently, the Company has reached initial commercial orders for DAXXIFY in China, marking the commencement of its commercialization implementation.

The Company believes that, as a strategic cornerstone in the injectable business, DAXXIFY will diversify the Company's product offerings and provide consumers with a broader range of premium choices. It will also serve as an additional growth driver, creating sustained consumables revenue and reinforcing the Company's leading position in the global wellness market.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, January 5, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*